一财社论：更重视临床反馈，集采新规开启改革新航标

Core Viewpoint - The new centralized procurement regulations effectively address various urgent concerns from society, reflecting the sensitivity and adaptability of the healthcare system to economic and social demands [2][5]. Group 1: Key Highlights of the New Procurement Regulations - The regulations respect and moderately meet clinical needs, improving the match between clinical demand and supply [2][3]. - More specific and quantifiable quality control standards for bidding companies have been introduced, such as requiring that production lines have not violated GMP standards in the past two years [2]. - A "first report leniency" mechanism has been introduced to address collusion in bidding, indicating a balanced approach to enforcement [2]. - The selection of price control "anchor points" has been optimized, moving away from simply choosing the lowest bid, and requiring companies to respond to concerns about low-price selections [2][3]. - A new opportunity for "revival of non-selected bids" has been added, encouraging more companies to participate at suitable prices [2]. Group 2: Implications for the Healthcare System - The new regulations provide a genuine institutional response to clinical needs, allowing for greater autonomy in medication use by doctors, which enhances supply-demand matching efficiency [3]. - The focus has shifted from merely controlling costs to emphasizing quality and effectiveness, prioritizing the interests of policyholders [3]. - The regulations contribute to alleviating the negative competition within the pharmaceutical industry, promoting upward competition among companies [3]. - The healthcare system's adaptability to patient satisfaction and preferences is crucial for its sustainability and competitiveness [4][5]. - Engaging policyholders and patients in the procurement process is essential for the healthcare system's growth and responsiveness to market demands [5].